CellFE®与DKFZ和TcellTech合作，推动用于细胞治疗的DNA载体基因工程的发展-动脉网

CellFE® Partners with DKFZ and TcellTech to Advance DNA Vector Genetic Engineering for Cellular Therapies

CISION 等信源发布 2025-04-30 19:59



可切换为仅中文







ALAMEDA, Calif.

阿拉米达，加利福尼亚州

，

April 30, 2025

2025年4月30日

/PRNewswire/ -- CellFE, a leader in non-viral gene editing technology, today announced a strategic collaboration with the Harbottle Lab at German Cancer Research Center (DKFZ) and its spin-out company, TcellTech. This partnership aims to advance personalized cell therapy development by combining CellFE's Ryva™ Mechanoporation System with TcellTech's innovative nanoSMAR gene expression DNA vector platform.

/PRNewswire/ -- 非病毒基因编辑技术领域的领导者CellFE今日宣布与德国癌症研究中心（DKFZ）的Harbottle实验室及其衍生公司TcellTech达成战略合作。此次合作旨在通过结合CellFE的Ryva™机械穿孔系统与TcellTech创新的nanoSMAR基因表达DNA载体平台，推动个性化细胞疗法的开发。

Together, the two technologies will address key challenges in the efficient use of DNA vectors for applications in cell therapy..

这两项技术将共同解决在细胞治疗应用中高效使用DNA载体的关键挑战。

继续阅读

CellFE and TcellTech technologies combine to open new pathways for safer, more scalable cell therapy development.

CellFE 和 TcellTech 技术相结合，为更安全、更可扩展的细胞疗法开发开辟了新途径。

Post this

发布这个

The collaboration brings together CellFE’s non-viral Ryva™ Mechanoporation System and TcellTech’s nanoSMAR DNA vector platform to address key challenges in cell engineering and enable safer, more consistent manufacturing of personalized cell therapies at scale.

此次合作将 CellFE 的非病毒 Ryva™ 机械穿孔系统与 TcellTech 的 nanoSMAR DNA 载体平台相结合，以解决细胞工程中的关键挑战，并实现更安全、更一致的大规模个性化细胞疗法生产。

Despite the immense therapeutic potential of DNA vectors, challenges such as efficient DNA delivery and maintaining cell viability remain significant obstacles in cell therapy development. This collaboration merges microfluidic-based mechanoporation with SMAR nanovectors to enable the efficient engineering of various cell lines.

尽管DNA载体具有巨大的治疗潜力，但高效的DNA递送和维持细胞活力等挑战仍然是细胞治疗开发中的重要障碍。此次合作将基于微流控的机械穿孔技术与SMAR纳米载体相结合，以实现对各种细胞系的有效工程改造。

Early results demonstrate strong compatibility between the technologies, with promising outcomes in generating stable cell lines expressing CARs or TCRs. This novel approach addresses key durability and safety challenges by eliminating the need for CRISPR in cellular engineering—paving the way for a smarter, safer gene-editing pipeline that minimizes off-target risks, improves consistency, and streamlines scalable cell therapy production..

早期结果表明，这些技术之间具有很强的兼容性，在生成稳定表达CAR或TCR的细胞系方面取得了可喜的成果。这种新颖的方法通过消除细胞工程中对CRISPR的需求，解决了关键的耐久性和安全性挑战——为更智能、更安全的基因编辑流程铺平了道路，最大限度地减少了脱靶风险，提高了一致性，并简化了可扩展的细胞治疗生产。

'Our partnership with TCellTech and DKFZ is redefining what's possible in gene delivery,' said Alla Zamarayeva, CEO at CellFE. 'By combining the Ryva™ System's high-performance delivery with nanoSMAR's scalable vector technology, we're enabling efficient, reliable payload delivery that meets the demands of next-generation cell engineering.'.

“我们与TCellTech和DKFZ的合作正在重新定义基因递送的可能性，”CellFE首席执行官阿拉·扎马雷耶娃表示。“通过将Ryva™系统的高性能递送与nanoSMAR的可扩展载体技术相结合，我们实现了高效、可靠的载荷递送，满足了下一代细胞工程的需求。”

Dr.

博士

Richard Harbottle

理查德·哈伯特

, co-founder of TcellTech and researcher at DKFZ, added, 'Using CellFE's technology to deliver our nanoSMAR vector platform enables the efficient genetic engineering of cells, demonstrating exceptional promise in a variety of cells, including those that are typically resistant to genetic modification.

TcellTech 的联合创始人、DKFZ 的研究员补充道：“使用 CellFE 的技术来递送我们的 nanoSMAR 载体平台，能够实现高效的细胞基因工程改造，在包括那些通常对基因改造具有抗性的细胞在内的多种细胞中展现了卓越的潜力。

nanoSMAR vectors offer a groundbreaking alternative to viral delivery – combining high payload capacity, sustained expression, and exceptional safety to unlock new potential in gene and cell therapy. This synergy not only addresses current limitations in gene delivery but also opens new possibilities for more sophisticated and personalized cell therapies targeting a wider range of diseases.'.

nanoSMAR载体为病毒递送提供了一种突破性的替代方案——结合了高载量、持续表达和卓越的安全性，解锁了基因和细胞治疗的新潜力。这种协同作用不仅解决了当前基因递送的局限性，还为针对更广泛疾病的更复杂和个性化的细胞治疗开启了新的可能性。

This collaborative new workflow holds significant promise for the future of regenerative medicine. By pairing the elegant scalability of CellFE's Ryva™ technology with the precision of TCellTech's nanoSMAR vector platform, the resulting workflow enables more robust, scalable, and efficient cell therapy manufacturing..

这种协作的新工作流程对再生医学的未来具有重要的前景。通过将CellFE的Ryva™技术的优雅可扩展性与TCellTech的nanoSMAR载体平台的精确性相结合，由此产生的工作流程能够实现更强大、可扩展且高效的细胞治疗制造。

The latest findings from this joint research will be presented by DKFZ researchers at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, scheduled for

德国癌症研究中心（DKFZ）的研究人员将在即将举行的美国基因与细胞治疗学会（ASGCT）第28届年会上展示这项联合研究的最新成果，会议计划于

May 13-17, 2025

2025年5月13日至17日

, at the New Orleans Ernest N. Morial Convention Center in

，在新奥尔良欧内斯特·N·莫里亚尔会议中心

New Orleans, Louisiana

路易斯安那州新奥尔良

. Abstract Details are below:

摘要详细信息如下：

Abstract Title: Exploring Mechanoporation for Efficient Genetic Modification Across Diverse Cell Types Using SMAR Vectors Abstract Number: 1678

摘要标题：使用SMAR载体探索不同细胞类型的机械穿孔高效基因修饰抽象编号：1678

Session Date and Time:

会议日期和时间：

Thursday, May 15

5月15日，星期四

，

5:30-7:00 PM

下午5:30-7:00

in Poster Hall I2

在海报大厅I2

Access Abstract:

访问摘要：

www.annualmeeting.asgct.org/program

About CellFE

关于CellFE

CellFE, a cutting-edge microfluidics company, is transforming the development and manufacturing of lifesaving cell therapies to make them more accessible to patients. CellFE aims to unlock the full potential of this transformative modality by tackling its key market challenges, notably high manufacturing costs and extended vein-to-vein timelines.

CellFE是一家前沿的微流体技术公司，正在变革救命细胞疗法的开发和制造，以使患者更容易获得这些疗法。CellFE旨在通过解决其关键市场挑战，特别是高昂的制造成本和漫长的静脉到静脉时间，来充分释放这种变革性模式的潜力。

With a focus on T-Cell, HSC, and iPSC-based therapies, CellFE's microfluidics-based gene-delivery technology, in conjunction with proprietary best-in-class workflows, targets critical bottlenecks in cell therapy manufacturing..

专注于T细胞、HSC和iPSC疗法，CellFE的基于微流控的基因递送技术结合其专有的最佳工作流程，针对细胞治疗生产中的关键瓶颈。

For more information, please visit:

欲了解更多信息，请访问：

www.cellfebiotech.com

。

About TcellTech

关于TcellTech

TCellTech GmbH is a clinical-stage biotechnology company founded in 2022 as a spin-out from the German Cancer Research Center (DKFZ) and is focused on developing universal, personalized adoptive T cell therapies to treat a broad range of cancers.

TCellTech GmbH 是一家临床阶段的生物技术公司，成立于2022年，是从德国癌症研究中心 (DKFZ) 分离出来成立的，专注于开发通用型、个性化的过继性T细胞疗法，以治疗多种癌症。

TCellTech has developed two technological platforms for the next generation of cancer immunotherapies:

TCellTech 已经开发了两个下一代癌症免疫治疗的技术平台：

(I) Discovery: an

（一）发现：一个

AI bioinformatics platform

人工智能生物信息学平台

to identify tumor reactive T cell receptors (selecTCR)

识别肿瘤反应性T细胞受体（selecTCR）

(II) Delivery: a high-performance gene expression

（II）传递：高性能基因表达

DNA vector platform